循证药学模型在临床应用管理工作的作用(3)
第1页 |
参见附件。
[2]世界卫生组织.世界卫生组织遏制抗生素耐药性的全球战略[J].医院感染监控信息,2002.16(1):26-52
[3]Brian L.Strom. Methodolgic Challenges to Studying Patient Safety and Comparative Effectiveness[J]. Med Care,2007,45(02):13-15
[4]Khatcheressian JL,Wolff AC,Smith TJ,et al.American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting[J].J Clin Oncol,2006,24(31):5091-5097
[5]Joan LR,Gerda T,Lynora S.Stability of heparin and physical compatibility of heparin/antibiotic solutions in concentrations appropriate for antibiotic lock therapy[J].J Antimicro Chemoth,2005,56:951-953
[6]Neumann PJ.Evidence-base and value-based formulary guidelines. Health Aff(Millwood),2004,23(1):124-134
[7]Straus SE,Richardson WS,Glasziou P,et al.Evidence-based medicine:how to practice and teach EBM(第2版)[M].北京:北京大学医学出版社,2006,3
[8]Steven G,Deeks Antiretroviral treatment of HIV infected adults[J].BMJ,2006,332:1489-1483
[9]王奇,温泽淮等.Meta分析在中药的多中心临床试验数据分析中的应用[J].广州中医药大学学报,1997,14(01)
[10]曹卉娟,刘建平.循证药学的基本概念及其应用[J].临床药物治疗杂志,2008,04
[11]唐镜波.以证据为基础的医学及药学信息[J].中国药学杂志,1998,33(10):624
[12]GRADE Working Group.Grading quality of evidence and strength of recommendations[J].BMJ,2004,328,1490-1487
[13] 陈钧,蒋学华.临床药学实践中的循证药学[J].中国药房,2001,12(2)
您现在查看是摘要介绍页,详见PDF附件。